Vanessa Biotech is seeking an IMPACT investor who is interested in being a part of delivering a
novel series of drugs to give hope where none currently exist.
The company is a clinical stage pharmaceutical company dedicated to discovering, developing,
and commercializing innovative products in areas of unmet medical needs.
Since 2015, the Company’s flagship product, Shylicine™, has been developed to treat the rare,
lethal microvillus inclusion disease (MVID), and has received “orphan drug” designation from
both the United States FDA and the European Medicine Agency. The drug is currently in clinical
trial phase in Turkey and the UAE. Saudi Arabia has approved the trial, but the company is
awaiting funding to enroll the remaining three patients for regulatory submission.
The company’s cholera drug candidate, AD 1005, is also in the clinical trial phase in Ghana and
Bangladesh. The company needs an additional 100 patients enrolled before submission to the
regulatory agencies for market approval.
The company manufacturers the Active Ingredient of their drugs at their production facility in
Spain. The drug is manufactured in Hungary.
VB is in need of approximately $1million to complete the cholera and MVID trials and is thus
seeking two to four investors to join its journey to regulatory approval.
The goal of the VB team is to use their experience to enhance shareholder value and fulfill its
mission to “give hope where none existed.”
To learn more about MVID, please click here: www.shylicine.com
For an executive summary pitch please click here: VB Presentation
Ready to Ask For Funding for your company?
Post a Funding RequestVanessa Biotech is no longer seeking funding.